Empirical antibiotics versus definitive antibiotics for Sepsis patients in Indonesia: A cost-effectiveness analysis
10
Issued Date
2024-10-01
Resource Type
eISSN
22313354
Scopus ID
2-s2.0-85205801590
Journal Title
Journal of Applied Pharmaceutical Science
Volume
14
Issue
10
Start Page
53
End Page
59
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Applied Pharmaceutical Science Vol.14 No.10 (2024) , 53-59
Suggested Citation
Noviyani R., Duong K.N.C., Ngo N.T.N., Kularatna S., Widatama A., Srinadi I.G.A.M. Empirical antibiotics versus definitive antibiotics for Sepsis patients in Indonesia: A cost-effectiveness analysis. Journal of Applied Pharmaceutical Science Vol.14 No.10 (2024) , 53-59. 59. doi:10.7324/JAPS.2024.195834 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/101616
Title
Empirical antibiotics versus definitive antibiotics for Sepsis patients in Indonesia: A cost-effectiveness analysis
Corresponding Author(s)
Other Contributor(s)
Abstract
Sepsis is a life-threatening issue worldwide. Antibiotics, including antibiotic treatment (ET) and culture-based treatment (CBT), are crucial therapies for sepsis treatment. However, there is insufficient evidence to compare their cost-effectiveness in Indonesia. This study evaluates the cost-effectiveness of these two antibiotic approaches in Indonesian patients. A decision-tree model was developed from a healthcare payer perspective, with a 1-year time horizon. The Incremental Cost-Effectiveness Ratio (ICER), i.e., the incremental cost per death averted, was estimated to compare the cost-effectiveness between two interventions. The willingness-to-pay threshold (WTP) was one to three times the gross domestic product (GDP) per capita (1 GDP per capital: IDR 72,333,083 [US$ 4,788]). One-way and probability sensitivity analyses were performed to assess the robustness of our findings. In base-case analysis, CBT prevented 347 patient deaths compared to ET, incurring an additional cost of IDR 8,873,397,000 (US$ 588,000) with an ICER of IDR 25,571,749 (US$ 1,693) per death averted. The probability of CBT being cost-effective was 72%–80% using the one- and three-times GDP per capita threshold, respectively. Utilizing the CBT for sepsis treatment is cost-effective compared with the ET. These findings can support clinicians and policymakers in facilitating the use of CBT in sepsis treatment in Indonesia.